Moreover, the release of 15-PGJ2-protein adducts by treated cancer cells as signalling molecules in vivo may play a promising role in anticancer therapy because these factors activate the Keap1/Nrf2 pathway, reduce oxidative stress, and by stabilizing oxygen metabolism and limiting the proliferation of endothelial cells, they prevent tumour-induced angiogenesis [79,80]. This evidence concerns the gene KEAP1 and cancer.